Revised SPC: Lemtrada (alemtuzumab) 12 mg concentrate for solution for infusion -

Revised SPC: Lemtrada (alemtuzumab) 12 mg concentrate for solution for infusion
Information type: Drug prescribing
Source: electronic Medicines compendium
Specialities: Cardiovascular system disorders | Haematological disorders | Liver disorders | Musculo-skeletal disorders | Neurological disorders | Stroke
Summary
The SPC advises treatment should only be initiated in adults with highly active relapsing remitting multiple sclerosis despite adequate course of treatment with at least 2 other disease modifying treatments, or where all other disease modifying treatments are otherwise unsuitable
UKMi comment
Sections 4.4 and 4.8 have also been updated to include warnings about the development of autoimmune hepatitis and other serious reactions temporally associated with alemtuzumab infusion.
Related links: